Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Transitional Cell 9Carcinoma, Merkel Cell 7Neoplasm Metastasis 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Melanoma 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Carcinoma, Renal Cell 3Ovarian Neoplasms 2Neuroendocrine Tumors 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Penile Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Motor Activity 1Microsatellite Instability 1

Interventions

ruxolitinib 9navitoclax 4Tacrolimus 4Cyclophosphamide 4Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3venetoclax 2fludarabine phosphate 2fludarabine 2Melphalan 2Busulfan 2veliparib 1selinexor 1pevonedistat 1luspatercept 1letermovir 1itacitinib 1imetelstat 1givinostat hydrochloride 1givinostat 1fedratinib 1elotuzumab 1canakinumab 1avelumab 1Valganciclovir 1Topotecan 1Therapeutics 1Stem Cell Transplantation 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Primary Myelofibrosis × avelumab × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡